Ipamorelin

A selective GH secretagogue known for clean growth hormone release without cortisol spikes.

IPAIpamorelin Acetate

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone through the ghrelin/GHSR pathway. It is considered one of the safest and most selective GH-releasing peptides because it does not significantly affect cortisol, prolactin, or ACTH levels — unlike older secretagogues like GHRP-6.

Key Benefits

Clean GH Release

Stimulates growth hormone without significantly raising cortisol, prolactin, or appetite — making it one of the cleanest GH peptides available.

Fat Loss

Elevated GH levels promote lipolysis, helping the body preferentially burn fat for energy.

Lean Muscle Support

Growth hormone promotes protein synthesis and muscle cell proliferation, supporting lean mass gains.

Improved Sleep

Enhances deep sleep stages when taken before bed, aligning with natural GH release rhythms.

Joint & Connective Tissue

GH stimulates collagen synthesis, supporting healthier joints, tendons, and skin.

Recovery Acceleration

Faster recovery from workouts and injuries through enhanced tissue repair processes.

Research Dosing Information

Common Dose

100-300 mcg per injection

Route

Subcutaneous injection

Frequency

1-3 times daily

Cycle Length

8-12 weeks

Not FDA-approved. Most commonly dosed at bedtime on an empty stomach. Often stacked with CJC-1295 (no DAC) for synergistic GH release. Dose 30+ minutes away from food to avoid insulin-mediated GH blunting.

Research Summary

Ipamorelin was first studied in the late 1990s and has been the subject of multiple clinical trials. Research demonstrates dose-dependent GH release with high selectivity — it does not stimulate ACTH, cortisol, or prolactin at therapeutic doses. A clinical trial in post-surgical patients demonstrated accelerated bowel recovery. Studies show it amplifies the natural pulsatile pattern of GH release rather than creating sustained elevation, which may be metabolically preferable.

Safety Considerations

Not FDA-approved for therapeutic use.
Generally well-tolerated in clinical trials.
May cause transient headache, flushing, or lightheadedness.
Water retention possible, especially at higher doses.
Contraindicated with active malignancies.
Blood glucose monitoring recommended for diabetic individuals.

Frequently Asked Questions

Is Ipamorelin better than GHRP-6?

Ipamorelin is considered more selective. Unlike GHRP-6, it does not significantly increase cortisol, prolactin, or appetite (ghrelin-mediated hunger). This makes it a cleaner option for GH stimulation.

Can I use Ipamorelin long-term?

Research protocols typically run 8-12 week cycles. Long-term safety data in humans is limited. Cycling with breaks is the common approach discussed in research literature.

Does Ipamorelin cause hunger?

Unlike GHRP-6 and GHRP-2, Ipamorelin has minimal effects on appetite. It selectively targets GH release without strongly activating the hunger-signaling ghrelin pathway.